AstraZeneca’s Dapagliflozin gets extended indication approval from DCGI to treat heart failure in…
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Deliver phase-III trial
Dapagliflozin meets primary endpoint in Deliver phase-III trial
Reduces risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction